Pharmaceutically active 3-(1,2,5,6-tetrahydropyridyl)-pyrrolopyridines
First Claim
1. A compound of the formula ##STR5## wherein one of A, B, D and E is N and the remaining three atoms are C;
- R1 and R2 are independently selected from hydrogen and C1 to C6 alkyl; and
R3, R4, R5 and R6 are independently selected from hydrogen, halogen, hydroxy, C1 -C6 alkyl, C1 -C8 alkoxy, phenyl-C1 -C6 alkoxy, phenoxy, --NR7 R8 wherein R7 and are independently selected from hydrogen, C1 -C6 alkyl, C1 -C6 alkanoyl, and COOR9 wherein R9 is hydrogen or C1 -C6 alkyl, cyano, COOR10 wherein R10 is hydrogen or C1 -C6 alkyl, and CONR11 R12 where R10 and R11 are independently selected from hydrogen and C1 -C6 alkyl and the pharmaceutically acceptable salts thereof.
1 Assignment
0 Petitions
Accused Products
Abstract
Compounds of the formula ##STR1## wherein one of A, B, D and E is N and the remaining three atoms are C; R1 and R2 are independently selected from hydrogen and C1 to C6 alkyl; and R3, R4, R5 and R6 are independently selected from hydrogen, halogen, hydroxy, C1 -C6 alkyl, C1 -C8 alkoxy, phenyl-C1 -C6 alkoxy, phenoxy --NR7 R8 wherein R7 and R8 are independently selected from hydrogen, C1 -C8 alkyl, C1 -C6 alkanoyl and COOR9 wherein R9 is hydrogen or C1 -C6 alkyl, cyano, COOR10 wherein R10 is hydrogen or C1 -C6 alkyl, and CONR11 R12 where R10 and R11 are independently selected from hydrogen and C1 -C6 alkyl, and the pharmaceutically acceptable salts thereof. The compounds are useful psychotherapeutics and may be used in treating obesity, depression and disorders wherein aggression is a symptom.
-
Citations
9 Claims
-
1. A compound of the formula ##STR5## wherein one of A, B, D and E is N and the remaining three atoms are C;
- R1 and R2 are independently selected from hydrogen and C1 to C6 alkyl; and
R3, R4, R5 and R6 are independently selected from hydrogen, halogen, hydroxy, C1 -C6 alkyl, C1 -C8 alkoxy, phenyl-C1 -C6 alkoxy, phenoxy, --NR7 R8 wherein R7 and are independently selected from hydrogen, C1 -C6 alkyl, C1 -C6 alkanoyl, and COOR9 wherein R9 is hydrogen or C1 -C6 alkyl, cyano, COOR10 wherein R10 is hydrogen or C1 -C6 alkyl, and CONR11 R12 where R10 and R11 are independently selected from hydrogen and C1 -C6 alkyl and the pharmaceutically acceptable salts thereof. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9)
- R1 and R2 are independently selected from hydrogen and C1 to C6 alkyl; and
Specification
-
- Resources
-
Current AssigneePfizer Inc.
-
Original AssigneePfizer Inc.
-
InventorsMacor, John E.
-
Primary Examiner(s)DENTZ, BERNARD I
-
Application NumberUS07/576,429Time in Patent Office372 DaysField of Search546/113, 514/300US Class Current514/300CPC Class CodesA61P 25/18 Antipsychotics, i.e. neurol...A61P 25/24 AntidepressantsA61P 25/26 Psychostimulants, e.g. nico...A61P 3/04 Anorexiants; Antiobesity ag...A61P 3/06 AntihyperlipidemicsC07D 471/04 Ortho-condensed systems
